Valeant Pharmaceuticals Intl (VRX) 21.62 $VRX
Valeant Pharmaceuticals International Rises 3.01% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 13, 11:45AM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $23.41 to a high of $24.67. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $23.90 on volume of 27.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 21.62 (-1.60)
SmarTrend Watching for Potential Pullback in Shares of Valeant Pharmaceuticals International After 9.87% Gain
Comtex SmarTrend(R) - Wed Jul 06, 11:50AM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $19.61 to a high of $21.93. Yesterday, the shares gained 9.9%, which took the trading range above the 3-day high of $21.65 on volume of 20.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 21.62 (-1.60)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 21.62 (-1.60), UTHR: 109.24 (-3.69), AZN: 30.16 (-0.04)
AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Arpita Dutt - Zacks Investment Research - Wed Jul 06, 8:39AM CDT
AstraZeneca (AZN) out-licensed global rights to tralokinumab for skin diseases to LEO Pharma.
AGN: 241.17 (+1.47), VRX: 21.62 (-1.60), AZN: 30.16 (-0.04), AMGN: 160.52 (-1.44)
Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology
CNW Group - Wed Jul 06, 12:30AM CDT
Second Published Phase 3 Trial to Demonstrate Significantly Greater Efficacy vs. Timolol Maleate 0.5%
VRX: 21.62 (-1.60), VRX.TO: 28.11 (-2.16)
Shares of VRX Down 30.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Jul 05, 12:49AM CDT
SmarTrend identified a Downtrend for Valeant Pharmaceuticals International (NYSE:VRX) on May 9th, 2016 at $29.49. In approximately 2 months, Valeant Pharmaceuticals International has returned 30.70% as of today's recent price of $20.44.
VRX: 21.62 (-1.60)
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
PR Newswire - Fri Jul 01, 1:00AM CDT
Valeant Receives Upfront Payment & Milestone Payments from AstraZeneca In Exchange for Termination of European Rights to Brodalumab
VRX: 21.62 (-1.60), AZN: 30.16 (-0.04), VRX.TO: 28.11 (-2.16)
Forget Valeant, Invest in These Attractive Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 2:52PM CDT
It's probably best to forget Valeant and instead invest in some other drug stocks with a favorable Zacks Rank.
VRX: 21.62 (-1.60), OGXI: 0.99 (unch), CPRX: 0.76 (-0.04), ARQL: 1.69 (-0.05), SPPI: 6.62 (-0.12)
SmarTrend Watching for Potential Rebound in Shares of Valeant Pharmaceuticals International After 5.77% Loss
Comtex SmarTrend(R) - Mon Jun 27, 12:26PM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $18.55 to a high of $20.13. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $20.21 on volume of 16.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRX: 21.62 (-1.60)
Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care
CNW Group - Mon Jun 27, 7:00AM CDT
40,000 Canadian Shoppers Voted Across 140 Categories for Most Trusted Retail Brands
VRX: 21.62 (-1.60), VRX.TO: 28.11 (-2.16)
Valeant Pharmaceuticals, Teva, Red Hat, Schlumberger, and Southwestern Energy Company and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Jun 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRX, TEVA, RHT, SLB and SWN.
VRX: 21.62 (-1.60), RHT: 73.66 (-0.25), TEVA: 54.46 (+2.00), SWN: 13.96 (-0.24), SLB: 78.88 (-0.77)
Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations
CNW Group - Fri Jun 17, 7:00AM CDT
$15 Million Investment in Steinbach, Manitoba Facility and Transfer of Xifaxan® and Apriso® Production
VRX: 21.62 (-1.60)
Follow Icahn Into Allergan Stock
Jack Foley - Amigobulls - Fri Jun 17, 5:08AM CDT
The biotech sector will recover its gains that it has lost since July 2015. Fundamentally strong Allergan will benefit handsomely.
AGN: 241.17 (+1.47), VRX: 21.62 (-1.60)
Should You Get Rid of Valeant Pharmaceuticals (VRX) Now?
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 7:31AM CDT
Valeant Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
VRX: 21.62 (-1.60), ORPN: 1.61 (-0.04)
Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin
CNW Group - Thu Jun 16, 7:00AM CDT
Inventive Eye Supplement from Bausch + Lomb Offers Consumers Greater Ease and Convenience
VRX: 21.62 (-1.60), VRX.TO: 28.11 (-2.16)
Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director
PR Newswire - Wed Jun 15, 7:00AM CDT
All Eleven Director Nominees Elected to the Board at Annual Meeting of Shareholders
VRX: 21.62 (-1.60), VRX.TO: 28.11 (-2.16)
Company News for June 14, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 9:10AM CDT
Companies in the News are: SYMC,VRX,SWHC,SAIC
SAIC: 59.94 (+0.57), VRX: 21.62 (-1.60), SWHC: 28.42 (-0.16), SYMC: 21.10 (+0.08)
Valeant's CEO Bought VRX Shares, But Here's Why You Shouldn't
Zacks Premium Research - Zacks Investment Research - Mon Jun 13, 1:39PM CDT
Joseph Papa, CEO of Valeant Pharmaceuticals, has bought close to $5 million of his company's shares. Is he bluffing though? Earnings are ultimately the key to investing, and here's how VRX's earnings expectations have been trending
VRX: 21.62 (-1.60)
Valeant Pharmaceuticals International Rises 3.01% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 13, 11:45AM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $23.41 to a high of $24.67. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $23.90 on volume of 27.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 21.62 (-1.60)
SmarTrend Watching for Potential Pullback in Shares of Valeant Pharmaceuticals International After 9.87% Gain
Comtex SmarTrend(R) - Wed Jul 06, 11:50AM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $19.61 to a high of $21.93. Yesterday, the shares gained 9.9%, which took the trading range above the 3-day high of $21.65 on volume of 20.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 21.62 (-1.60)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 21.62 (-1.60), UTHR: 109.24 (-3.69), AZN: 30.16 (-0.04)
AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Arpita Dutt - Zacks Investment Research - Wed Jul 06, 8:39AM CDT
AstraZeneca (AZN) out-licensed global rights to tralokinumab for skin diseases to LEO Pharma.
AGN: 241.17 (+1.47), VRX: 21.62 (-1.60), AZN: 30.16 (-0.04), AMGN: 160.52 (-1.44)
Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology
CNW Group - Wed Jul 06, 12:30AM CDT
Second Published Phase 3 Trial to Demonstrate Significantly Greater Efficacy vs. Timolol Maleate 0.5%
VRX: 21.62 (-1.60), VRX.TO: 28.11 (-2.16)
Shares of VRX Down 30.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Jul 05, 12:49AM CDT
SmarTrend identified a Downtrend for Valeant Pharmaceuticals International (NYSE:VRX) on May 9th, 2016 at $29.49. In approximately 2 months, Valeant Pharmaceuticals International has returned 30.70% as of today's recent price of $20.44.
VRX: 21.62 (-1.60)
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
PR Newswire - Fri Jul 01, 1:00AM CDT
Valeant Receives Upfront Payment & Milestone Payments from AstraZeneca In Exchange for Termination of European Rights to Brodalumab
VRX: 21.62 (-1.60), AZN: 30.16 (-0.04), VRX.TO: 28.11 (-2.16)
Forget Valeant, Invest in These Attractive Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 2:52PM CDT
It's probably best to forget Valeant and instead invest in some other drug stocks with a favorable Zacks Rank.
VRX: 21.62 (-1.60), OGXI: 0.99 (unch), CPRX: 0.76 (-0.04), ARQL: 1.69 (-0.05), SPPI: 6.62 (-0.12)
SmarTrend Watching for Potential Rebound in Shares of Valeant Pharmaceuticals International After 5.77% Loss
Comtex SmarTrend(R) - Mon Jun 27, 12:26PM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $18.55 to a high of $20.13. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $20.21 on volume of 16.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRX: 21.62 (-1.60)
Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care
CNW Group - Mon Jun 27, 7:00AM CDT
40,000 Canadian Shoppers Voted Across 140 Categories for Most Trusted Retail Brands
VRX: 21.62 (-1.60), VRX.TO: 28.11 (-2.16)
Valeant Pharmaceuticals, Teva, Red Hat, Schlumberger, and Southwestern Energy Company and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Jun 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRX, TEVA, RHT, SLB and SWN.
VRX: 21.62 (-1.60), RHT: 73.66 (-0.25), TEVA: 54.46 (+2.00), SWN: 13.96 (-0.24), SLB: 78.88 (-0.77)
Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations
CNW Group - Fri Jun 17, 7:00AM CDT
$15 Million Investment in Steinbach, Manitoba Facility and Transfer of Xifaxan® and Apriso® Production
VRX: 21.62 (-1.60)
Follow Icahn Into Allergan Stock
Jack Foley - Amigobulls - Fri Jun 17, 5:08AM CDT
The biotech sector will recover its gains that it has lost since July 2015. Fundamentally strong Allergan will benefit handsomely.
AGN: 241.17 (+1.47), VRX: 21.62 (-1.60)
Should You Get Rid of Valeant Pharmaceuticals (VRX) Now?
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 7:31AM CDT
Valeant Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
VRX: 21.62 (-1.60), ORPN: 1.61 (-0.04)
Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin
CNW Group - Thu Jun 16, 7:00AM CDT
Inventive Eye Supplement from Bausch + Lomb Offers Consumers Greater Ease and Convenience
VRX: 21.62 (-1.60), VRX.TO: 28.11 (-2.16)
Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director
PR Newswire - Wed Jun 15, 7:00AM CDT
All Eleven Director Nominees Elected to the Board at Annual Meeting of Shareholders
VRX: 21.62 (-1.60), VRX.TO: 28.11 (-2.16)
Company News for June 14, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 9:10AM CDT
Companies in the News are: SYMC,VRX,SWHC,SAIC
SAIC: 59.94 (+0.57), VRX: 21.62 (-1.60), SWHC: 28.42 (-0.16), SYMC: 21.10 (+0.08)
Valeant's CEO Bought VRX Shares, But Here's Why You Shouldn't
Zacks Premium Research - Zacks Investment Research - Mon Jun 13, 1:39PM CDT
Joseph Papa, CEO of Valeant Pharmaceuticals, has bought close to $5 million of his company's shares. Is he bluffing though? Earnings are ultimately the key to investing, and here's how VRX's earnings expectations have been trending
VRX: 21.62 (-1.60)
